Manufacturing

Sartorius BIA Separations and Teknova will collaborate to combine their technologies in an effort to streamline the downstream purification process.

Samsung Biologics plans to invest more than ₩1.9 trillion (US$1.5 billion) in the new Incheon, South Korea, facility, which will hold a manufacturing capacity of 180,000 L.

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

Webinar Date/Time: Wednesday, March 29th 2023 7am PDT | 10am EST | 4pm CEST

Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.

Pharmaceutical companies have shifted their approach to development of vaccines as a result of the COVID-19 pandemic.

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.

Webinar Date/Time: Tue, Apr 11, 2023 11:00 AM EDT

Process and plasmid design optimization, disposable equipment, and flexible platform processes all play important roles.

Decreasing vein to vein time saves lives.

There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.

Shifts in pharmaceutical packaging have spurred tremendous growth in the pre-filled syringe fill/finish industry.

Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.

The trends shaping the growth of the biologics outsourcing industry demand attention.

AbbVie and Capsida have expanded their existing collaboration to advance three new gene therapy programs.

Agilent’s therapeutic nucleic acids facility gains architectural design support from CRB.

Webinar Date/Time: Tue, Mar 14, 2023 11:00 AM EDT

There is an evolution in the way technology and best practices are blended to meet cold-chain supply requirements for temperature-sensitive biotherapeutics.

The new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing.

Improvements to Fluid Air’s Magnaflo filter blowback system are intended to increase powder yield in PolarDry Models 001 and 004.

A slew of late-stage clinical trials is expected to push new regenerative medicines onto the market in the next few years.

Improvement in viral vector yield has become integral to new cell and gene therapy product development.

In part 2 of this article, results from the testing of a next generation convecdiff membrane are discussed.

Alternative approaches to freeze drying are gaining popularity and will help to overcome some of the challenges associated with conventional lyophilization.